ONCY Share Price Performance
US$1.28
-0.03 (-2.29%)
Price US$1.28
Share PriceUS$1.28
Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?
Sep 03
Oncolytics Biotech Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
ONCY Community Narratives
There are no narratives available yet.
Oncolytics Biotech Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.30
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Oncolytics Biotech Inc. Competitors
Snowflake Analysis
About ONCY
- Founded
- 1998
- Employees
- 28
- CEO
- WebsiteView website
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Canadian Market Performance
- 7 Days: 1.1%
- 3 Months: 10.3%
- 1 Year: 22.1%
- Year to Date: 20.3%
The market has climbed 1.1% in the last 7 days, lead by the Materials sector with a gain of 2.7%. The market is up 22% over the last 12 months. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›